(News Bulletin 247) – AlphaValue on Tuesday raised its recommendation on Ipsen shares to ‘buy’ versus ‘accumulate’ so far, citing an ‘attractive small pharmaceutical value’.
‘After a promising 2022 year-end, followed by a strong performance in the first half, we are raising our price target by 23%, thanks to a robust pipeline combined with encouraging clinical results in recent months, favorable trials expected in the coming months and a solid balance sheet”, he concludes.
Its target thus rises to 168 euros against 137 euros previously.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
